Literature DB >> 7942168

Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta.

R E Brenner1, U Vetter, A M Bollen, M Mörike, D R Eyre.   

Abstract

Urinary excretion of type I collagen cross-linked N-telopeptides was studied in 52 children and adolescents with osteogenesis imperfecta (OI) and found to be above the 75th percentile of controls in 44 of the patients. OI patients suffering from fractures during the preceding 6 months had significantly higher values (p < 0.05). In contrast, patients with better motor performance tended to have lower values (p = 0.059). The concentration of urinary type I collagen cross-linked N-telopeptides was positively correlated with urinary calcium excretion (p < 0.05), which was found to be elevated in 20 of the patients. Our results show that during childhood and adolescence in OI not only the synthesis but also the turnover of mature cross-linked type I collagen is disturbed and provide evidence that bone resorption rates are elevated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7942168     DOI: 10.1002/jbmr.5650090706

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  10 in total

1.  Increased susceptibility to microdamage in Brtl/+ mouse model for osteogenesis imperfecta.

Authors:  Mathieu S Davis; Bethany L Kovacic; Joan C Marini; Albert J Shih; Kenneth M Kozloff
Journal:  Bone       Date:  2011-12-20       Impact factor: 4.398

2.  Intravenous pamidronate in juvenile osteoporosis.

Authors:  N J Shaw; C M Boivin; N J Crabtree
Journal:  Arch Dis Child       Date:  2000-08       Impact factor: 3.791

3.  Bone resorptive activity of human peripheral blood mononuclear cells after fusion with polyethylene glycol.

Authors:  Edwin Manrique; Luz M Castillo; Oswaldo Lazala; Carlos A Guerrero; Orlando Acosta
Journal:  J Bone Miner Metab       Date:  2016-03-11       Impact factor: 2.626

4.  Co-existence of osteogenesis imperfecta and hyperparathyroidism.

Authors:  T Zimmermann-Belsing; A M Lund; L Christensen; U Feldt-Rasmussen
Journal:  J Endocrinol Invest       Date:  1999 Jul-Aug       Impact factor: 4.256

Review 5.  Osteogenesis imperfecta: practical treatment guidelines.

Authors:  F Antoniazzi; M Mottes; P Fraschini; P C Brunelli; L Tatò
Journal:  Paediatr Drugs       Date:  2000 Nov-Dec       Impact factor: 3.022

Review 6.  Efficacy of oral etidronate for skeletal diseases in Japan.

Authors:  Jun Iwamoto; Tsuyoshi Takeda; Yoshihiro Sato
Journal:  Yonsei Med J       Date:  2005-06-30       Impact factor: 2.759

7.  Nuclear retention of COL1A1 messenger RNA identifies null alleles causing mild osteogenesis imperfecta.

Authors:  D A Redford-Badwal; M L Stover; M Valli; M B McKinstry; D W Rowe
Journal:  J Clin Invest       Date:  1996-02-15       Impact factor: 14.808

8.  Eleven years of experience with bisphosphonate plus alfacalcidol treatment in a man with osteogenesis imperfecta type I.

Authors:  Jun Iwamoto; Yoshihiro Sato; Mitsuyoshi Uzawa; Hideo Matsumoto
Journal:  Ther Clin Risk Manag       Date:  2012-12-28       Impact factor: 2.423

9.  Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta.

Authors:  Lena Lande Wekre; Erik F Eriksen; Jan A Falch
Journal:  Arch Osteoporos       Date:  2011-04-14       Impact factor: 2.617

10.  Novel mutations in FKBP10 and PLOD2 cause rare Bruck syndrome in Chinese patients.

Authors:  Peiran Zhou; Yi Liu; Fang Lv; Min Nie; Yan Jiang; Ou Wang; Weibo Xia; Xiaoping Xing; Mei Li
Journal:  PLoS One       Date:  2014-09-19       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.